AIM
ONCE

Acrospire Investment Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Acrospire Investment Management’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-100
Closed -$6K – 2531
2016
Q3 		$6K Buy
+100
New +$5.76K ﹤0.01% 1809

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acrospire Investment Management's ONCE Position: Q4 2016 in Review

Acrospire Investment Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2016, closing a stake of 100 shares — an estimated $6K sold.

Acrospire Investment Management first reported a position in ONCE in Q3 2016 and held it in 1 quarter. The position peaked at $6K in Q3 2016. 119 funds tracked by Wall St. Rank hold ONCE as of Q4 2016.

  • Acrospire Investment Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Acrospire Investment Management sold 100 Spark Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $6K.
  • Acrospire Investment Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Spark Therapeutics, Inc. Common Stock position peaked at $6K in Q3 2016.
  • 119 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Acrospire Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.